Development of vaccine for Clostridium difficile infection using membrane fraction of nontoxigenic Clostridium difficile
Although standard antibiotic therapy is performed for diarrhea and pseudomembranous colitis caused by Clostridium difficile, a high recurrence rate of C. difficile infection (CDI) remains a major problem. We previously showed that a membrane fraction of nontoxigenic C. difficile (ntCDMF) was effecti...
Saved in:
Published in | Microbial pathogenesis Vol. 123; pp. 42 - 46 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.10.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Although standard antibiotic therapy is performed for diarrhea and pseudomembranous colitis caused by Clostridium difficile, a high recurrence rate of C. difficile infection (CDI) remains a major problem. We previously showed that a membrane fraction of nontoxigenic C. difficile (ntCDMF) was effective as a vaccine antigen by in vitro experiments. In this study, we examined whether ntCDMF had an in vivo effect in animal challenge experiments. By intrarectal immunization with ntCDMF, the number of C. difficile cells in feces of mice was decreased approximately 99% compared to the control mice. In addition, survival rate of C. difficile-challenged hamsters was increased almost 30% by immunization with ntCDMF. These results showed that ntCDMF could be a practical vaccine candidate.
•ntCDMF was examined as a vaccine candidate for CDI.•The best route for ntCDMF immunization was intrarectal.•ntCDMF immunization decreased the number of C. difficile cells in feces of mice.•ntCDMF immunization was effective in C. difficile challenge using a hamster model.•ntCDMF can be a vaccine candidate for CDI. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0882-4010 1096-1208 |
DOI: | 10.1016/j.micpath.2018.06.039 |